Health committee  After all the messages I've given about a comprehensive approach, you want me to zero in on one.

Health committee  I would say the most important thing would be a national drug observatory. Included in that would be prescription-monitoring programs in each jurisdiction together with an early warning system. We need to have the data. We have it for physical health issues. If there is a flu ac

Health committee  I would look at it as preventing the use and abuse of any psychoactive substance, so I would put it as part of a bigger.... I think opioids are one of those that we're dealing with today. Meth was in the past. Heroin was in the past. I think we need to look at it as I had mention

Health committee  Certainly when we look at prevention, we look at risk and protective factors. For instance, we're looking at resiliency. When you look at the risk factors, some of the risk factors are genetic. Some of the risk factors are the environment. When you look at protective factors, it

Health committee  I'm familiar with Gabor, the second individual you mentioned.

Health committee  To repeat what I said earlier, I think it's both. I think we need to look at the prevention opportunities that are there. We also need to look at current practices, whether those practices be in education and prescribing or whether those practices be in the delivery of treatment

Health committee  If I understand your question correctly, you're talking about different populations that have been affected. Matthew has some more recent information, but I would say that the population we are seeing is the older adults. As well, in some of the work on utilization, we are seeing

Health committee  It's very comprehensive. That's why I indicated I'd be more than happy to share that report. It speaks to the latest evidence and it speaks to the strength of the evidence along that continuum, including the prescribing of opioids.

Health committee  I'm sorry to say that I don't think there is one cause, and I do think it's all the things that you touched on. It is about prevention. It is about prescriber education. It is the whole continuum. It is about enforcement and what more can be done there. It is about the public kno

Health committee  When I talk about treatment, we've been focusing on safe injection sites and safe consumption sites. There is an array of treatment options and I do want to say that when I talked about those standards from the WHO and UNODC, there is a variety of treatment options for the treatm

Health committee  Absolutely, it is. That comprehensive approach, when I referred to the “First Do No Harm” road map, did speak to all of that comprehensive approach. It did speak to prevention. It talked about consumer education and public awareness; how to have that conversation with your physic

Health committee  Our group is really an organization that looks at the evidence. I think Ms. Geller has spoken to the evidence on consumption sites. We also look at ensuring that the public is protected. I think there is always a balance. Right now, in terms of the bill and what I have been told,

Health committee  Again, we don't have a position, per se. We ask what the evidence says about consumption sites. What does it say in terms of being part of a continuum of care? We support that it be part of the continuum of care. What we have been told is that every effort is being made to ensure

Health committee  I do want to stress one thing. When we first did our “First Do No Harm” report, there was an impression that there was one solution to the issue. As all of us have said, I think, there is no one magic bullet, no one solution. I think we do need to address prescriber education.

Health committee  Good morning, Mr. Chair and members of the committee. My name is Rita Notarandrea and I'm CEO of the Canadian Centre on Substance Abuse. I am joined today by my colleague Matthew Young, a senior research and policy analyst at CCSA. Dr. Young leads our drug use epidemiology rese